#1
|
||||
|
||||
Ïðèìåíåíèå îáû÷íîãî (íåðàöåìè÷åñêîãî) àäðåíàëèíà ÷åðåç íåáóëàéçåð ïðè ëîæíîì êðóïå.
Âîò ðåøèë ïîäåëèòüñÿ.
Ðåêîìåíäîâàíî äëÿ âðà÷åé è ðîäèòåëåé ================================================== ======== Åñëè ó âàñ åñòü çàìå÷àíèÿ - ïèøèòå, äîáàâëÿéòå êîììåíòàðèè. ================================================== ======== [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Âèäåî British Red Cross î ïîìîùè ðåáåíêó ïðè ëîæíîì êðóïå. *** Íèêàêîé íàôòèçèí â íåáóëàéçåðå íå íóæåí! Âìåñòî íåãî áåðåì àäðåíàëèí (epinephrine). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Authors' conclusions: Nebulized epinephrine is associated with clinically and statistically significant transient reduction of symptoms of croup 30 minutes post‐treatment. Evidence does not favor racemic epinephrine or L‐epinephrine, or IPPB over simple nebulization. The authors note that data and analyses were limited by the small number of relevant studies and total number of participants and thus most outcomes contained data from very few or even single studies. Çàêëþ÷åíèå àâòîðîâ <îáçîð 8 èññëåäîâàíèé, 225 ó÷àñòíèêîâ>: èñïîëüçîâàíèå àäðåíàëèíà â íåáóëàéçåðå ñâÿçàíî ñ êëèíè÷åñêè è ñòàòèñòè÷åñêè çíà÷èìûì âðåìåííûì óìåíüøåíèåì ñèìïòîìîâ êðóïà íà ïðîòÿæåíèè 30 ìèí ïîñëå ëå÷åíèÿ. Èññëåäîâàíèå íå îòäàåò ïðåäïî÷òåíèÿ ðàöåìè÷åñêîìó àäðåíàëèíó èëè åãî L-èçîìåðó <ðå÷ü èäåò î ò.í. îïòè÷åñêèõ èçîìåðàõ ïðåïàðàòà>, à òàêæå ïåðåìåæàþùåìóñÿ ïîëîæèòåëüíîìó äàâëåíèþ â êîíöå âûäîõà ïåðåä ÏÅÐÅÄ ÎÁÛ×ÍÛÌ ÍÅÁÓËÀÉÇÅÐÍÛÌ ÏÐÈÌÅÍÅÍÈÅÌ. Àâòîðû îòìå÷àþò, ÷òî äàííûå è àíàëèç áûëè îãðàíè÷åíû íåáîëüøèì êîëè÷åñòâîì ïîäõîäÿùèõ èññëåäîâàíèé è îáùåãî ÷èñëà ó÷àñòíèêîâ, ïîýòîìó áîëüøèíñòâî èñõîäîâ âçÿòî èç íåñêîëüêèõ, ïîðîé äàæå åäèíè÷íûõ èññëåäîâàíèé. *** Adrenaline for croup.pdf Èç ïðèêðåïëåííîãî äîêóìåíòà (ýòî åùå îäíî èññëåäîâàíèå): Summing up, the evidence presented in this review shows that nebulization with 3 to 5 ml of adrenaline (1:1000) is a safe treatment with few side effects. Based on this evidence, we recommend nebulization with 3 to 5 ml of adrenaline (1:1000) for children suffering from acute inflammatory obstructions of the airways. Ñóììèðóÿ, äîêàçàòåëüñòâà, ïðåäñòàâëåííûå â îáçîðå, ïîêàçûâàþò, ÷òî íåáóëàéçåðíàÿ òåðàïèÿ ñ 3-5 ìë àäðåíàëèíà (1:1000) <1:1000 - ýòî îáû÷íàÿ êîíöåíòðàöèÿ àäðåíàëèíà â àìïóëå, 1 ìã/ìë; 1 ìë - ýòî 1 ãðàìì = 1000 ìã; 1 ìã/ìë - ýòî 1:1000> - ýòî áåçîïàñíîå ëå÷åíèå ñ íåáîëüøèì êîëè÷åñòâîì ïîáî÷íûõ ýôôåêòîâ. Îñíîâûâàÿñü íà ýòîì äîêàçàòåëüñòâå, ìû ðåêîìåíäóåì íåáóëèçàöèþ ñ 3-5 ìë àäðåíàëèíà (1:1000) äëÿ äåòåé, ñòðàäàþùèõ îò îñòðîé âîñïàëèòåëüíîé îáñòðóêöèè âåðõíèõ äûõàòåëüíûõ ïóòåé. *** [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ].. Earlier work from the Australian group found that a single oral dose of dexamethasone (0.6 mg/kg) or inhaled budesonide (2 mg) results in a significant reduction in symptoms by one hour with virtually no subsequent need for nebulised adrenaline and a significantly reduced hospital stay.5 To emphasise the impact of steroid treatment on morbidity of children hospitalised with croup, it is worth noting that, of the 170 children who received steroids in the two studies3,5, only one child required adrenaline after the first hour in contrast to 20% of the 30 children in the placebo group. Áîëåå ðàííÿÿ ðàáîòà àâñòðàëèéñêîé ãðóïïû îáíàðóæèëà, ÷òî îäíîêðàòíûé ïðèåì äåêñàìåòàçîíà (0,6 ìã / êã) èëè èíãàëÿöèîííûé áóäåñîíèä <ãëþêîêîðòèêîñòåðîèäíûé ãîðìîí> (2 ìã) ïðèâîäèò ê çíà÷èòåëüíîìó ñíèæåíèþ ñèìïòîìîâ íà îäèí ÷àñ ïðàêòè÷åñêè áåç ïîñëåäóþùåé íåîáõîäèìîñòè èíãàëÿöèè àäðåíàëèíà è çíà÷èòåëüíî ìåíüøåé ïðîäîëæèòåëüíîñòè ãîñïèòàëèçàöèè. ×òîáû ïîä÷åðêíóòü ðîëü ëå÷åíèÿ ñòåðîèäàìè íà çàáîëåâàåìîñòü äåòåé, ãîñïèòàëèçèðîâàííûõ ñ êðóïîì, ñòîèò îòìåòèòü, ÷òî èç 170 äåòåé, êîòîðûå ïîëó÷èëè ñòåðîèäû â äâóõ èññëåäîâàíèÿõ, òîëüêî îäíîìó ðåáåíîêó ïîòðåáîâàëñÿ àäðåíàëèí ïîñëå ïåðâîãî ÷àñà, â îòëè÷èå îò 20% äåòåé â ãðóïïå ïëàöåáî, ñîñòîÿùåé èç 30 äåòåé. *** Áóäåñîíèä äëÿ íåáóëàéçåðà: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ].. Ñëåäóåò îòìåòèòü, ÷òî ïî èíñòðóêöèè ìàêñèìàëüíî ðàçðåøåííàÿ ñóòî÷íàÿ äîçà äëÿ äåòåé - 800 ìêã (0,8 ìã).  îòëè÷èå îò óïîìèíàåìîé â ïîñëåäíåì èññëåäîâàíèè äîçû 2 ìã (2000 ìêã). *** Êñòàòè, òî æå ïîñëåäíåå èññëåäîâàíèå ([Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]..) îòäàåò ïðåäïî÷òåíèå ïðèåìó äåêñàìåòàçîíà ÷åðåç ðîò(â èññëåäîâàíèè áûëè óêàçàíû äîçû îò 0,15 äî 0,6 ìã/êã áåç óêàçàíèÿ íà çíà÷èòåëüíóþ ðàçíèöó â èñõîäàõ ) ïî ñîîáðàæåíèÿì ýôôåêòèâíîñòè è öåíû ïðåïàðàòà. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Äåêñàìåòàçîí âûïóñêàåòñÿ â òàáëåòêàõ ïî 0,0005 ã (0,5 ìã â îäíîé òàáëåòêå). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ðåæèì äîçèðîâàíèÿ Èíäèâèäóàëüíûé. Âíóòðü ïðè òÿæåëûõ çàáîëåâàíèÿõ â íà÷àëå ëå÷åíèÿ íàçíà÷àþò äî 10-15 ìã/ñóò, ïîääåðæèâàþùàÿ äîçà ìîæåò ñîñòàâëÿòü 2-4.5 ìã è áîëåå â ñóò.  îñòðîì ïåðèîäå ïðè ðàçëè÷íûõ çàáîëåâàíèÿõ è â íà÷àëå ëå÷åíèÿ äåêñàìåòàçîí ïðèìåíÿþò â áîëåå âûñîêèõ äîçàõ. ================================================== ===== Åñëè â ÷åì-òî íåïðàâ ÿ èëè àâòîðû ïðåäñòàâëåííûõ äîêóìåíòîâ, òî êîëëåãè ïîïðàâÿò ìåíÿ. |
#2
|
|||
|
|||
Âñå òàê, òîëüêî â Ðîññèè ðàöåìè÷åñêîãî àäðåíàëèíà íåò, à îáû÷íûé â íåáóëàéçåð íå çàëüåøü. Áóäåñîíèä - îòëè÷íî ðàáîòàåò.  èíñòðóêöèè ê Ïóëüìèêîðòó äîçà äî 2 ìã â ñóòêè [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
P.S. Çà íàôòèçèí íàäî îòðûâàòü ðóêè. |
#3
|
|||
|
|||
À ïî÷åìó îáû÷íûé àäðåíàëèí íå çàëüåøü?
|
#4
|
||||
|
||||
Äà, õîðîøèé âîïðîñ íàñ÷åò îáû÷íîãî àäðåíàëèíà!
À ïî÷åìó, ñîáñòâåííî? Äàéòå, ïîæ-òà, ññûëêè. Îñîáåííî, ó÷èòûâàÿ èíôîðìàöèþ çäåñü: http://forums.rusmedserv.com/blog.php?b=299 >> - L-àäðåíàëèí (îáû÷íûé àìïóëüíûé àäðåíàëèí, ïðèì. ïåðåâ.) äîçèðóåòñÿ 0,5 ìë / êã çà îäíó äîçó (íå áîëåå 5 ìë) 1:1000 ðàçâåäåíèÿ. Îí èíãàëèðóåòñÿ ÷åðåç íåáóëàéçåð áîëåå 15 ìèíóò. è çäåñü: http://forums.rusmedserv.com/showthread.php?t=48891 |
#5
|
||||
|
||||
íå, ýòî íå òàê ðàáîòàåò. ñîâñåì äàæå íàîáîðîò
äàâàéòå ëó÷øå Âû äàäèòå ññûëêè íà òî, ÷òî îáû÷íûé àäðåíàëèí ìîæíî ëèòü â íåáóëàéçåð âî âñåõ ãàéäëàéíàõ è ó÷åáíèêàõ, â êîòîðûõ ÿ ÷èòàë ïðî èíãàëèðîâàíèå àäðåíàëèíà - ãîâîðèëîñü î ðàöåìè÷åñêîì àäðåíàëèíå ìåíÿ ìàìà ó÷èëà: íå çíàåøü ÿãîäêó - íå åøü åå
__________________
Òîëüêî ïîìíèòå: ôîðóì - íå çàìåíà î÷íîìó âðà÷ó, à ëå÷åíèå ïî èíòåðíåòó - ÷ðåâàòî ñìåðòüþ îò îïå÷àòêè. Ñ óâàæåíèåì, Ñåðãåé Àëåêñàíäðîâè÷. |
#6
|
|||
|
|||
À êàê æå òîãäà ññûëêè íà èíãàëèðîâàíèå àäðåíàëèíà 1:1000? Òî, ÷òî â ïîêàçàíèÿõ ðîññèéñêèõ âîçìîæíîñòü åãî èíãàëÿöèîííîãî èñïîëüçîâàíèÿ íå çâó÷èò íå ãîâîðèò î òîì, ÷òî åãî íåëüçÿ èñïîëüçîâàòü ñ òàêîé öåëüþ. Çà ðóáåæîì ÷òî -àäðåíàëèí 1:1000 äðóãîé? Äà, âîçìîæíî, â çàðóáåæíûõ èíñòðóêöèÿõ è çâó÷èò åãî èíãàëÿöèîííîå ïðèìåíåíèå, à ó íàñ íåò, íî ñóòü äåëà îò ýòîãî íå ìåíÿåòñÿ.  èíñòðóêöèè ïî ïóëüìèêîðòó â ïîêàçàíèÿõ ñòåíîç, ê ïðèìåðó, íå çâó÷èò, à â èíñòðóêöèè ê âèôåðîíó íàïèñàíî, ÷òî äåéñòâóåò.
ß ê òîìó, ÷òî âñå æå â Ðîññèè åãî èñïîëüçóþò ïðè ñòåíîçå(íåìíîãèå). ß íå ñ öåëüþ ïîóìíè÷àòü, à ñ öåëüþ ðàçîáðàòüñÿ. |
#7
|
||||
|
||||
Âîò ÷òî ïèøåò Êîõðýéí:
Nebulized epinephrine was associated with significantly shorter hospital stay than placebo (one RCT, MD -32.0 hours; 95% CI -59.1 to -4.9). Comparing racemic and L-epinephrine, no difference in croup score was found after 30 minutes (SMD 0.33; 95% CI -0.42 to 1.08). After two hours, L-epinephrine showed significant reduction compared with racemic epinephrine (one RCT, SMD 0.87; 95% CI 0.09 to 1.65). There was no significant difference in croup score between administration of nebulized epinephrine via IPPB versus nebulization alone at 30 minutes (one RCT, SMD -0.14; 95% CI -1.24 to 0.95) or two hours (SMD -0.72; 95% CI -1.86 to 0.42). AUTHORS' CONCLUSIONS: Nebulized epinephrine is associated with clinically and statistically significant transient reduction of symptoms of croup 30 minutes post-treatment. Evidence does not favor racemic epinephrine or L-epinephrine, or IPPB over simple nebulization. Cochrane Database Syst Rev. 2013 Oct 10;10:CD006619. Nebulized epinephrine for croup in children [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
|
#8
|
||||
|
||||
Èíòåðåñåí òàêæå êåéñ â ïîëíîòåêñòå:
Nebulized racemic epinephrine used in the treatment of severe asthmatic exacerbation: a case report and literature review [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] èç-çà ôðàãìåíòà íèæå: There does not appear to be any difference in efficacy between nebulized L-epinephrine and racemic epinephrine (an equimolar mixture of L- and D-epinephrine) if used in equipotent doses for the treatment of croup.3,25 Likewise, L-epinephrine and racemic epinephrine have demonstrated similar results when used for other airway diseases, such as post-extubation stridor.26 Although racemic epinephrine was used in this case, primarily because of clinical convenience, it is likely that L-epinephrine would also have been efficacious given its apparent equivalence to racemic epinephrine, as demonstrated in the above studies. This is of particular importance to Canadian clinicians in light of the recent manufacturer's announcement that racemic epinephrine (Vaponephrine) has been discontinued and will no longer be available in Canada. Thus, when nebulized epinephrine is indicated, L-epinephrine will soon be the only option available to Canadian emergency physicians. Dosing equivalencies between L-epinephrine and racemic epinephrine formulations are outlined in Table 2.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#9
|
||||
|
||||
Öèòàòà:
- L-àäðåíàëèí (îáû÷íûé àìïóëüíûé àäðåíàëèí, ïðèì. ïåðåâ.) äîçèðóåòñÿ 0,5 ìë / êã çà îäíó äîçó (íå áîëåå 5 ìë) 1:1000 ðàçâåäåíèÿ. Îí èíãàëèðóåòñÿ ÷åðåç íåáóëàéçåð áîëåå 15 ìèíóò. ? Èç âàøåãî ïîñòà: http://forums.rusmedserv.com/blog.php?b=299 |
#10
|
||||
|
||||
Çíàþ, êîëëåãà, íå ïðèäèðàéòåñü
Êîãäà ÿ íåñêîëüêî ëåò íàçàä ïåðåâîäèë òó ñòàòüþ, è äîøåë äî ýòîé ñòðî÷êè - ÿ ñèëüíî ñïîòêíóëñÿ. ß íà÷àë ÷èòàòü â ÷åì ðàçíèöà ðàöåìè÷åñêîãî àäðåíàëèíà è íàøåãî, è òàê æå êàê è Âû, ðåøèë ÷òî îí ïîäõîäèò. Çàòåì íå îäèí ðàç áûë îñàæåí çà ïîäîáíûå ðåêîìåíäàöèè íà ÐÌÑ, ïî÷èòàë åùå, è òàê òîëêîì è íå ðàçîáðàâøèñü, ðåøèë, ÷òî îò ãðåõà - íå ñòàíó åãî íàçíà÷àòü (è ïî ðîññèéñêèì ðåêîìåíäàöèÿì íåëüçÿ, è ïî èìïîðòíûì - íå ñîîòâåòñòâóåò) ß ñàì íå çíàþ òî÷íîãî îòâåòà, è ñàì áû õîòåë åãî óçíàòü. Ïðèãëàñèë â òîïèê êëèíè÷åñêèõ ôàðìàêîëîãîâ è âñåõ ìóäðûõ êîëëåã, âîçìîæíî íàì ðàçúÿñíÿò ïî÷åìó íåëüçÿ, èëè ïî÷åìó ìîæíî. ...Ïðîñòî ñàìà ïîäà÷à Âàøåãî âîïðîñà íåâåðíà. Ñêàæåì, åñëè ÿ ñïðîøó - ãäå íàïèñàíî, ÷òî âèôåðîí íå íóæåí ïðè êðóïå, äàéòå ññûëêó - òî ýòî âîïðîñ "íàèçíàíêó". Âðÿä ëè åñòü òàêèå ññûëêè - íà êàæäîå íåâåðíîå íàçíà÷åíèå íèêàêèõ ññûëîê íå íàïàñåøüñÿ. Õîòÿ ñðàâíåíèå, êîíå÷íî, íåòî÷íîå.
__________________
Òîëüêî ïîìíèòå: ôîðóì - íå çàìåíà î÷íîìó âðà÷ó, à ëå÷åíèå ïî èíòåðíåòó - ÷ðåâàòî ñìåðòüþ îò îïå÷àòêè. Ñ óâàæåíèåì, Ñåðãåé Àëåêñàíäðîâè÷. |
#11
|
||||
|
||||
>> Efficacy: Racemic & L-epinephrine are equally efficacious.
L – epinephrine (use if racemic epinephrine unavailable) Dose:0.5 mL/kg/dose of 1:1000 ... Maximum Dose: 5 mL Ïîäðîáíåå â äîêóìåíòå. |
#12
|
||||
|
||||
Ðàçæåëòèë äâà ñîîáùåíèÿ îò DrVad
(ó íàñ âå÷íî âñå èíòåðåñíîå - â "ñêðûâòûõ ïîñòàõ) íàäåþñü, Âàäèì Âàëåðüåâè÷ íà ìåíÿ íå îáèäèòñÿ
__________________
Òîëüêî ïîìíèòå: ôîðóì - íå çàìåíà î÷íîìó âðà÷ó, à ëå÷åíèå ïî èíòåðíåòó - ÷ðåâàòî ñìåðòüþ îò îïå÷àòêè. Ñ óâàæåíèåì, Ñåðãåé Àëåêñàíäðîâè÷. |
#13
|
||||
|
||||
È â îáùåì ïî òåìå.
Ïðèìåíÿòü, íà ìîé âçãëÿä ñòîèò. Õîòü ýôôåêò è äëèòñÿ íå áîëåå 2-õ ÷àñîâ, íî â ïîñëåäñòâèè äåòè íå óõóäøàëèñü: Compared to no medication, inhaled epinephrine improved croup symptoms in children at 30 minutes following treatment (three studies, 94 children). This treatment effect disappeared two hours after treatment (one study, 20 children). However, children's symptoms did not become worse than prior to treatment. No study measured adverse events. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#14
|
||||
|
||||
È åùå ïðî ýêâèâàëåíòíîñòü ðàöåìàòà è L-èçîìåðà:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Evidence does not favor racemic epinephrine or L‐epinephrine, or IPPB over simple nebulization. |
#15
|
||||
|
||||
Sorry, íå çàìåòèë. Ïîñëåäíÿÿ ññûëêà óæå áûëà.
Ñ÷èòàþ, ÷òî âîïðîñ ðåøåí. |